Invivyd, Inc. announced positive initial results from the ongoing CANOPY Phase 3 pivotal clinical trial of VYD222, a broadly neutralizing, half-life extended monoclonal antibody candidate, for the prevention of symptomatic COVID-19. "VYD222 produced high serum virus neutralizing antibody (sVNA) titer levels against XBB.1.5 in the IC cohort, essentially replicating the titer levels observed in Phase 1 clinical trial of VYD222 in healthy volunteers. The company also encouraged by the potential early signal of strong clinical protection from symptomatic COVID-19 in the CANOPY clinical trial to date, which would be expected given the high VYD222sVNA titer levels and dose selected.

The CANOPY clinical trial utilizes an innovative immunobridging design in which pharmacokinetic (PK) data from participants and potency data (IC50 values) are used to calculate sVNA titer levels. As characterized in Science Translational Medicine paper, the company believe calculated sVNA titer levels can be bridged back to the titer levels and corresponding clinical efficacy observed in EVADE, pivotal clinical trial of ADG20 for prevention of COVID-19.